Stockscreener 앱 받기
68.50
2.59%
1.73
시간 외 거래:
68.50
전일 마감가:
$66.77
열려 있는:
$66.54
하루 거래량:
645.55K
Relative Volume:
0.68
시가총액:
$4.72B
수익:
-
순이익/손실:
$-255.84M
주가수익비율:
-16.25
EPS:
-4.2149
순현금흐름:
$-232.60M
1주 성능:
-6.82%
1개월 성능:
-0.62%
6개월 성능:
+87.52%
1년 성능:
+69.39%
1일 변동 폭
$66.01
$69.59
1주일 범위
$66.01
$76.27
52주 변동 폭
$26.20
$84.56
Apogee Therapeutics Inc Stock (APGE) Company Profile
명칭
Apogee Therapeutics Inc
전화
650-394-5230
주소
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
68.50 | 4.60B | 0 | -255.84M | -232.60M | -4.2149 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | Truist | Hold |
| 2026-01-22 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | 개시 | Wolfe Research | Peer Perform |
| 2025-12-17 | 개시 | Stephens | Overweight |
| 2025-12-10 | 개시 | Deutsche Bank | Buy |
| 2025-11-03 | 개시 | Craig Hallum | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-09-25 | 개시 | RBC Capital Mkts | Outperform |
| 2025-07-07 | 재확인 | BTIG Research | Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2024-11-25 | 개시 | Canaccord Genuity | Buy |
| 2024-05-10 | 개시 | BofA Securities | Buy |
| 2023-12-20 | 개시 | BTIG Research | Buy |
| 2023-08-08 | 개시 | Guggenheim | Buy |
| 2023-08-08 | 개시 | Jefferies | Buy |
| 2023-08-08 | 개시 | Stifel | Buy |
| 2023-08-08 | 개시 | TD Cowen | Outperform |
| 2023-08-08 | 개시 | Wedbush | Outperform |
모두보기
Apogee Therapeutics Inc 주식(APGE)의 최신 뉴스
This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Apogee Therapeutics Inc. (NASDAQ:APGE) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Truist initiates Apogee Therapeutics stock with Hold on high bar - Investing.com
Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF) - The Globe and Mail
Aug Spikes: Is Apogee Therapeutics Inc backed by strong institutional buyingQuarterly Risk Review & Short-Term High Return Strategies - baoquankhu1.vn
BTIG Research Reiterates "Buy" Rating for Apogee Therapeutics (NASDAQ:APGE) - MarketBeat
HighVista Strategies LLC Grows Position in Apogee Therapeutics Inc. $APGE - MarketBeat
APGEApogee Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - AOL.com
Boxer Capital Management LLC Acquires New Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Braidwell LP Sells 39,767 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
CEO Michael Henderson Sells 20,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 20,000 Shares - MarketBeat
Apogee Therapeutics CEO Sells 20,000 Shares - TradingView
Apogee Therapeutics (APGE) CEO sells 20,000 shares in pre-set 10b5-1 plan - Stock Titan
The Technical Signals Behind (APGE) That Institutions Follow - Stock Traders Daily
Barclays PLC Buys 33,494 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
A Look At Apogee Therapeutics (APGE) Valuation After Wider Losses And A New Shelf Registration - Sahm
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
Wedbush Raises Price Target on Apogee Therapeutics (APGE) - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Jefferies Financial Group Inc. Sells 74,273 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
RBC Capital Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN
Performance Recap: What is Apogee Therapeutics Incs 5 year growth outlookJuly 2025 Pullbacks & Accurate Buy Signal Alerts - baoquankhu1.vn
Apogee Therapeutics (NASDAQ:APGE) Insider Carl Dambkowski Sells 5,500 Shares - MarketBeat
Apogee Therapeutics (APGE) CMO sells shares under 10b5-1 trading plan - Stock Titan
T. Rowe Price (APGE) holds 6.21M shares, 11.3% stake disclosed - Stock Titan
Vanguard Group Inc. Has $89.22 Million Stock Holdings in Apogee Therapeutics Inc. $APGE - MarketBeat
Rafferty Asset Management LLC Acquires 23,585 Shares of Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics (APGE) Gets a Buy from Mizuho Securities - The Globe and Mail
Citi Remains a Buy on Apogee Therapeutics (APGE) - The Globe and Mail
CFO at Apogee Therapeutics (APGE) sells 2,000 shares in planned trades - Stock Titan
Apogee Therapeutics Teases 52-Week Zumi Durability Data, Phase III Path at TD Cowen Conference - MarketBeat
RBC Capital Reaffirms Their Hold Rating on Apogee Therapeutics (APGE) - The Globe and Mail
Is Rising R&D Spend And New Equity Shelf Altering The Investment Case For Apogee Therapeutics (APGE)? - Yahoo Finance
APGE: RBC Capital Lowers Price Target to $82, Maintains Sector P - GuruFocus
Apogee Therapeutics (APGE) Stock Analysis: Exploring a 47.76% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $95.00 - MarketBeat
RBC Lowers Price Target on Apogee Therapeutics to $82 From $83, Keeps Sector Perform, Speculative Risk - marketscreener.com
Apogee’s Deeper Losses and New Shelf Filing Test Its High-Risk Pipeline Strategy (APGE) - Sahm
Apogee Therapeutics Stock: Clinical-Stage Risks, Unproven Pipeline, and Uncertain Path to Profitability - TipRanks
Decoding Apogee Therapeutics Inc (APGE): A Strategic SWOT Insigh - GuruFocus
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook By Investing.com - Investing.com Australia
RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook - Investing.com Australia
Key facts: Apogee Therapeutics posts $285.6M loss; plans Phase 3 trial - TradingView
APGE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Apogee Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Apogee Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Apogee Therapeutics Inc (APGE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):